Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 3
2004 2
2005 1
2008 2
2009 1
2010 2
2011 1
2012 5
2014 1
2017 3
2018 3
2019 1
2020 3
2021 2
2022 6
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.
Hosoda S, Suda G, Sho T, Ogawa K, Kimura M, Yang Z, Yoshida S, Kubo A, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Miyagishima T, Sakamoto N. Hosoda S, et al. Among authors: meguro t. Liver Cancer. 2022 Oct 31;12(2):156-170. doi: 10.1159/000527759. eCollection 2023 Jun. Liver Cancer. 2022. PMID: 37325489 Free PMC article.
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
Suda G, Baba M, Yamamoto Y, Sho T, Ogawa K, Kimura M, Hosoda S, Yoshida S, Kubo A, Fu Q, Yang Z, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Kobayashi T, Tsunematsu I, Sakamoto N. Suda G, et al. Among authors: meguro t. J Med Virol. 2023 Feb;95(2):e28452. doi: 10.1002/jmv.28452. J Med Virol. 2023. PMID: 36597900
Assessment of postoperative common bile duct stones after endoscopic extraction and subsequent cholecystectomy.
Sugiura R, Nakamura H, Horita S, Meguro T, Sasaki K, Kagaya H, Yoshida T, Aoki H, Morita T, Fujita M, Tamoto E, Fukushima M, Ashitate Y, Ueno T, Tsutaho A, Kuwatani M, Sakamoto N. Sugiura R, et al. Among authors: meguro t. Surg Endosc. 2022 Sep;36(9):6535-6542. doi: 10.1007/s00464-022-09017-z. Epub 2022 Jan 18. Surg Endosc. 2022. PMID: 35041052 Free article.
A rare case of pancreatic acinar cell carcinoma presenting a submucosal tumor.
Sugiura R, Kagaya H, Nakamura H, Horita S, Meguro T, Sasaki K, Yoshida T, Aoki H, Kuwatani M, Fukushima M, Morita T, Fujita M, Okamura K, Tamoto E, Ueno T, Tsutaho A, Inoue A, Takahashi T. Sugiura R, et al. Among authors: meguro t. Endosc Ultrasound. 2023 Mar-Apr;12(2):300-302. doi: 10.4103/EUS-D-22-00078. Endosc Ultrasound. 2023. PMID: 37148142 Free PMC article. No abstract available.
A rare case of pancreatic ductal adenocarcinoma with ossification mimicking a pancreatic stone impaction.
Sugiura R, Sasaki K, Nakamura H, Horita S, Meguro T, Kagaya H, Yoshida T, Aoki H, Morita T, Fujita M, Okamura K, Tamoto E, Fukushima M, Ueno T, Tsutaho A, Inoue A, Takahashi T. Sugiura R, et al. Among authors: meguro t. Endosc Ultrasound. 2023 Mar-Apr;12(2):290-291. doi: 10.4103/EUS-D-22-00008. Endosc Ultrasound. 2023. PMID: 36204801 Free PMC article. No abstract available.
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.
Kawamoto Y, Yuki S, Sawada K, Nakamura M, Muto O, Sogabe S, Shindo Y, Ishiguro A, Sato A, Tsuji Y, Dazai M, Okuda H, Meguro T, Harada K, Sekiguchi M, Okada K, Ito YM, Sakata Y, Sakamoto N, Komatsu Y. Kawamoto Y, et al. Among authors: meguro t. Oncologist. 2022 Aug 5;27(8):e642-e649. doi: 10.1093/oncolo/oyac086. Oncologist. 2022. PMID: 35579511 Free PMC article. Clinical Trial.
Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201).
Kawamoto Y, Yuki S, Meguro T, Hatanaka K, Uebayashi M, Nakamura M, Okuda H, Iwanaga I, Kato T, Nakano S, Sato A, Harada K, Oba K, Sakata Y, Sakamoto N, Komatsu Y. Kawamoto Y, et al. Among authors: meguro t. Oncologist. 2022 May 6;27(5):340-e374. doi: 10.1093/oncolo/oyab062. Oncologist. 2022. PMID: 35303078 Free PMC article. Clinical Trial.
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150.
Sho T, Suda G, Yamamoto Y, Furuya K, Baba M, Ogawa K, Kubo A, Tokuchi Y, Fu Q, Yang Z, Kimura M, Kitagataya T, Maehara O, Ohnishi S, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Suzuki K, Izumi T, Meguro T, Terashita K, Takagi T, Ito J, Kobayashi T, Miyagishima T, Sakamoto N. Sho T, et al. Among authors: meguro t. Cancers (Basel). 2022 Aug 15;14(16):3938. doi: 10.3390/cancers14163938. Cancers (Basel). 2022. PMID: 36010930 Free PMC article.
Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies.
Nakatsumi H, Komatsu Y, Muranaka T, Yuki S, Kawamoto Y, Harada K, Dazai M, Tateyama M, Sasaki Y, Miyagishima T, Tsuji Y, Katagiri M, Nakamura M, Sogabe S, Hatanaka K, Meguro T, Kobayashi T, Ishiguro A, Muto O, Shindo Y, Kotaka M, Ando T, Takagi R, Sakamoto N, Sakata Y. Nakatsumi H, et al. Among authors: meguro t. Front Oncol. 2022 Nov 9;12:939425. doi: 10.3389/fonc.2022.939425. eCollection 2022. Front Oncol. 2022. PMID: 36439491 Free PMC article.
39 results